Application of the Conversation Map™ in Type 2 Diabetes Mellitus with Insulin Treatment

Taiwan • 2014

Map Tools are effective for patients with a new prescription or change of insulin regimen; glycemic control unchanged but fewer events for the intervention group; HbA1c: MapTools (MT): baseline 10.84% +/- 1.96 to post-study 7.49% +/- 1.05 (n=51, p < 0.05) Usual Care (UC): baseline 11.31% +/- 1.77 to post-study 8.51% +/- 1.48 (p < 0.05); Body Weight: MT baseline 69.61 kg +/- 15.21 to post-study 72.34 kg +/- 15.37 (p < 0.05) UC: baseline 68.73 kg +/- 15.21 to post-study 70.03 kg +/- 17.16 (p < 0.05); Fasting Plasma Glucose: MT: baseline 211 mg/dL +/- 104.03 to post-study 149 mg/dL +/- 53.05 (p < 0.05) UC: baseline 232.65 mg/dL +/- 101.90 to post-study 166.58 mg/dL +/- 53.77; Systolic BP: MT: baseline 143 mmHg +/- 26.04 to post-study 122 mmHg +/- 27.66 UC: 168.66 mmHg +/- 22.73 to post-study 137 mmHg +/- 19.92; Diastolic BP: MT: baseline 82.50 mmHg +/- 13.47 to post-study 71.86 mmHg +/- 17.62 UC: baseline 82.43 mmHg +/- 17.75 to post-study 81.22 mmHg +/- 14.41.

---

Li, C.L.; Yang, Y.S.; Wu, Y.C.; Lu, Y.L.; Kornlius, E.; Chen, Y.J.; Lin, Y.T.; Huang, C.M. Application of the Conversation Map® in Type 2 Diabetes Mellitus with Insulin Treatment. American Diabetes Association 74th Scientific Sessions. June 13–17, 2014, San Francisco. P-695.

 

More Case Studies